PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-2.27%
Revenue decline while Medical - Pharmaceuticals median is 2.59%. Seth Klarman would investigate if market share loss is temporary.
-1.69%
Cost reduction while Medical - Pharmaceuticals median is 2.02%. Seth Klarman would investigate competitive advantage potential.
-4.56%
Gross profit decline while Medical - Pharmaceuticals median is 1.30%. Seth Klarman would investigate competitive position.
-2.35%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.15%
Other expenses change of 25.15% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
2.21%
Operating expenses growth 50-90% of Medical - Pharmaceuticals median of 2.78%. Mohnish Pabrai would examine discipline.
-1.05%
Total costs reduction while Medical - Pharmaceuticals median is 3.82%. Seth Klarman would investigate advantages.
-5.56%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
1.90%
D&A growth 1.1-1.25x Medical - Pharmaceuticals median of 1.66%. John Neff would investigate asset efficiency.
-22.98%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-21.20%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-29.63%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-28.00%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
41.98%
Other expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
-25.73%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-24.00%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-24.55%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-26.28%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-24.57%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-26.27%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-26.27%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
0.00%
Share count reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.02%. Joel Greenblatt would investigate strategy.
No Data
No Data available this quarter, please select a different quarter.